SCHEMBL21386697

SCHEMBL21386697

CCN1CCN(c2ccc(N)c(Nc3ncc(/C=C(\F)c4c(Cl)c(OC)cc(OC)c4Cl)cn3)c2C)CC1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PDGFRA P16234 3/20 0.39
▸ PDGFRB P09619 1/20 0.39
▸ FGFR1 P11362 12/20 0.38
▸ FGFR4 P22455 10/20 0.38
▸ FGFR3 P22607 8/20 0.36
▸ FGFR2 P21802 5/20 0.36
▸ KDR P35968 3/20 0.36
▸ FLT3 P36888 3/20 0.36
▸ JAK2 O60674 2/20 0.36
▸ ABL1 P00519 2/20 0.36
▸ INSR P06213 2/20 0.36
▸ LCK P06239 2/20 0.36
▸ FYN P06241 2/20 0.36
▸ YES1 P07947 2/20 0.36
▸ LYN P07948 2/20 0.36
▸ RET P07949 2/20 0.36
▸ MET P08581 2/20 0.36
▸ ROS1 P08922 2/20 0.36
▸ KIT P10721 2/20 0.36
▸ SRC P12931 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21756516 0.92 FGFR1 (0.36) PDGFRAPDGFRBFGFR1FGFR4FGFR3
SCHEMBL21756558 0.87 FGFR1 (0.39) PDGFRAPDGFRBFGFR1FGFR4FGFR3
SCHEMBL23365599 0.87 FGFR4 (0.42) PDGFRAFGFR1FGFR4FGFR3FGFR2
SCHEMBL21756515 0.85 FGFR4 (0.52) FGFR1FGFR4FGFR3FGFR2
SCHEMBL21756524 0.76 FGFR4 (0.68) FGFR1FGFR4FGFR3FGFR2
SCHEMBL21756570 0.75 FGFR4 (0.49) FGFR1FGFR4FGFR3FGFR2
SCHEMBL21386669 0.74 FGFR1 (0.51) FGFR1FGFR4ALK
SCHEMBL21756544 0.69 FGFR1 (0.38) FGFR1FGFR4FGFR3FGFR2KDR
SCHEMBL21386618 0.69 BACE1 (0.34) FGFR1FGFR2
SCHEMBL22451238 0.68 FGFR4 (0.32) FGFR1FGFR4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11008292-B2 FGFR4 inhibitor and preparation method and use thereof GUANGDONG ZHONGSHENG PHARMACEUTICAL CO., LTD (CN) 2021-05-18 — — US disclosed
US-20200062716-A1 FGFR4 INHIBITOR AND PREPARATION METHOD AND USE THEREOF GUANGDONG ZHONGSHENG PHARMACEUTICAL CO., LTD (CN) 2020-02-27 — — US disclosed
EP-3543227-A1 FGFR4 INHIBITOR AND PREPARATION METHOD AND USE THEREOF Guangdong Zhongsheng Pharmaceutical Co., Ltd (CN) 2019-09-25 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11008292-B2 FGFR4 inhibitor and preparation method and use thereof FGFR4, FGFR1, FGFR2 PDGFRA 59/4885PDGFRB 36/4885FGFR1 2/4885
US-20200062716-A1 FGFR4 INHIBITOR AND PREPARATION METHOD AND USE THEREOF FGFR4, FGFR1, FGFR2 PDGFRA 59/4885PDGFRB 36/4885FGFR1 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback